Abpro Holdings, Inc. is a biotechnology company dedicated to developing next-generation antibody therapeutics, which helps in improving the lives of patients with severe and life-threatening diseases. The Company is focused on novel antibody constructs for immuno-oncology and ophthalmology. By leveraging its DiversImmune and MultiMab antibody discovery and engineering platforms, it is engaged in developing a pipeline of antibodies, both independently and through collaborations with global pharmaceutical and research institutions. Its two lead product candidates, ABP-102 and ABP-201, feature its next generation tetravalent antibody format (TetraBi antibody format), which binds to two different targets with two distinct binding sites per target. ABP-102 is designed to redirect a patientâ€™s immune system to fight cancer by engaging T cells through co-targeting human epidermal growth factor receptor 2 (HER2), and cluster of differentiation 3 (CD3), T-cell co-receptor.

Employees

Sector

Biotechnology & Medical Research

More about the company

Capitalization	11.49M 9.91M 8.94M 8.58M 15.65M 1.06B 16.38M 106M 42.35M 506M 43.12M 42.2M 1.81B	P/E ratio 2023	-8.46x	P/E ratio 2024	-2.41x
Enterprise value	11.97M 10.32M 9.31M 8.94M 16.3M 1.1B 17.06M 110M 44.11M 527M 44.92M 43.96M 1.89B	EV / Sales 2023	-	EV / Sales 2024	497x
Free-Float	15.56%	Yield 2023 *	-	Yield 2024	-

Feb. 24	Abpro Holdings, Inc.(NasdaqCM:ABP) dropped from S&P TMI Index	CI
Feb. 19	Abpro Holdings, Inc.(OTCPK:ABPO) dropped from NASDAQ Composite Index	CI
Feb. 03	Abpro Holdings, Inc. Announces Board and Committee Resignations	CI
Jan. 23	Abpro Holdings, Inc. Announces Board and Committee Changes	CI
Jan. 16	Abpro Holdings, Inc. announced that it expects to receive $0.147 million in funding	CI
Jan. 06	Abpro, Celltrion Say Solid Cancer Tumor Therapy Investigational New Drug Application Receives US FDA Clearance	MT
Jan. 06	Abpro Holdings, Inc. and Celltrion, Inc. Announce U.S. FDA IND Clearance for Lead Multispecific Antibody Cancer Candidate ABP-102 / CT-P72	CI
Dec. 15	Abpro Holdings announces submission of an IND application to initiate a Phase 1 clinical trial of T cell engager ABP-102/CT-P72 for HER2-positive cancers	RE
Dec. 15	Abpro Holdings, Inc. and Celltrion, Inc. Announces Submission of an IND Application to Initiate a Phase 1 Clinical Trial of T Cell Engager ABP-102/CT-P72 for HER2-Positive Cancers	CI
Nov. 14	Abpro Holdings, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2025	CI
Nov. 07	Abpro Holdings files prospectus related to the offer and resale of up to 9.78 million shares of common stock - SEC filing	RE
25-10-22	Abpro Holdings Inc - to effect one-for-thirty reverse stock split - SEC filing	RE
25-10-02	Abpro Holdings, Inc. Announces Termination of Robert J. Markelewicz as Chief Medical Officer, Effective November 30, 2025	CI

Jan. 15	Abpro’s Lead Program ABP-102 Featured in Celltrion Presentation at the 44th Annual J.P. Morgan Healthcare Conference	AQ
Jan. 06	Abpro and Celltrion, Inc. Announce U.S. FDA IND Clearance for Lead Multispecific Antibody Cancer Candidate ABP-102 / CT-P72	AQ
Dec. 15	Abpro Holdings Announces Submission of an IND Application to Initiate a Phase 1 Clinical Trial of T cell engager ABP-102/CT-P72 for HER2-positive Cancers	AQ
Dec. 09	Abpro Granted Nasdaq Listing Extension to Pursue Compliance and Strategic Objectives	AQ
Nov. 04	Abpro and Celltrion to Present Preclinical Data for CT-P72/ABP-102 at SITC 2025, Highlighting a Next-Generation HER2×CD3 T-Cell Engager	AQ

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5d. change	1-year change	3-years change	Capi.($)
ABPRO CORPORATION	-.--%	-.--%	-	-	296K
LONZA GROUP AG	-2.02%	-5.97%	-11.64%	-10.60%	45.49B
BEONE MEDICINES AG	+2.79%	-5.01%	+17.18%	+26.18%	33.41B
CELLTRION, INC.	+0.47%	-10.90%	+17.49%	+52.87%	31.32B
IQVIA HOLDINGS INC.	-2.25%	-2.42%	-5.92%	-20.53%	29.29B
REVOLUTION MEDICINES, INC.	-1.24%	-3.55%	+150.89%	+294.55%	19.5B
ASCENDIS PHARMA A/S	+1.39%	+3.06%	+58.83%	+111.91%	14.77B
MEDPACE HOLDINGS, INC.	+0.26%	+4.17%	+44.47%	+134.63%	13.36B
EUROFINS SCIENTIFIC SE	-1.64%	-5.25%	+24.86%	+3.99%	13.22B
IONIS PHARMACEUTICALS, INC.	-1.49%	-8.76%	+115.30%	+104.25%	12.23B
Average	-0.37%	-3.69%	+45.72%	+77.47%	23.62B
Weighted average by Cap.	-0.42%	-4.59%	+30.87%	+56.30%

	2023	2024
Net sales	122K 105K 94.96K 91.11K 166K 11.21M 174K 1.12M 450K 5.38M 458K 448K 19.23M	183K 158K 142K 137K 249K 16.82M 261K 1.68M 675K 8.07M 687K 672K 28.84M
Net income	-11.71M -10.09M -9.11M -8.74M -15.94M -1.08B -16.68M -108M -43.15M -516M -43.93M -43M -1.85B	-7.23M -6.24M -5.63M -5.4M -9.85M -665M -10.31M -66.54M -26.66M -319M -27.14M -26.56M -1.14B
Net Debt	2.17M 1.87M 1.69M 1.62M 2.96M 200M 3.09M 19.98M 8M 95.68M 8.15M 7.97M 342M	478K 412K 372K 357K 651K 43.93M 681K 4.4M 1.76M 21.07M 1.79M 1.76M 75.34M

Abpro Corporation Stock Nasdaq

Equities

US0008501076

Biotechnology & Medical Research

Valuation: Abpro Corporation

Latest news: Abpro Corporation

Press Releases: Abpro Corporation

Other Biotechnology & Medical Research

Financials

Company Profile